
Hormone Therapy for Breast Cancer

Education for Patients and the Public

Correspondence: Exon Publications, Brisbane, Australia; Email: books@exonpublications.com

Cite as: Hormone Therapy for Breast Cancer . Brisbane (AU): Exon Publications; 2024. Published on 12 Dec.

DOI: <https://doi.org/10.36255/hormone-therapy-breast-cancer>

Copyright: Exon Publications

License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 (CC BY-NC-ND 4.0)

<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Abstract

Hormone therapy is a targeted treatment approach for breast cancer that leverages the relationship between hormones like estrogen and progesterone and the growth of certain types of breast cancer cells. This therapy aims to block or lower hormone levels in the body, thereby slowing or stopping the growth of hormone receptor-positive breast cancers. This article explores the role of hormone therapy in breast cancer treatment, detailing its uses, drugs, mechanisms, administration, preparation, effectiveness, and the challenges associated with its side effects. It is designed to provide patients, families, and caregivers with a clear understanding of this critical treatment option,

helping them navigate the journey with confidence and clarity.

Keywords: aromatase inhibitors; complications and side effects of hormone therapy; effectiveness of hormone therapy; estrogen receptor modulators; hormone receptor-positive breast cancers; how does hormone therapy work for breast cancer; how is hormone therapy administered for breast cancer; life after hormone therapy; ovarian suppression; post-hormone therapy care and recovery; preparation for hormone therapy; what are the hormone therapy drugs for breast cancer; what is hormone therapy; when is hormone therapy used for breast cancer

Introduction

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of women and a smaller percentage of men. Among the various types of breast cancer, a significant number are hormone receptor-positive, meaning their growth is influenced by hormones like estrogen and progesterone. Hormone therapy has revolutionized the treatment of this type of cancer, offering an effective way to reduce the risk of recurrence and improve survival rates. Understanding how hormone therapy works and its place in the broader treatment plan is essential for patients and their loved ones to make informed decisions (1-5).

What is Hormone Therapy?

Hormone therapy for breast cancer is a treatment designed to block or reduce the effects of hormones that fuel the growth of certain cancer cells. It is particularly effective for hormone receptor-positive breast cancers, where cancer cells have receptors that bind to hormones like estrogen and progesterone, promoting their growth. Hormone therapy is not the same as hormone replacement therapy, which is used to alleviate menopausal symptoms. Instead, it works to deprive cancer cells of the hormonal signals they

need to grow and divide. It is a systemic treatment, meaning it can affect cancer cells throughout the body.

When is Hormone Therapy used for Breast Cancer?

Hormone therapy is commonly used in several scenarios for breast cancer treatment. It may be employed as adjuvant therapy after surgery to reduce the risk of recurrence by eliminating any remaining cancer cells. It is also used as neoadjuvant therapy before surgery to shrink tumors, making them easier to remove. For patients with advanced or metastatic breast cancer, hormone therapy can help control the disease and alleviate symptoms. Hormone therapy is generally recommended for cancers that are hormone receptor-positive, determined through tests performed on the tumor tissue. Genetic factors, such as mutations in the ESR1 gene, may also influence treatment decisions.

What are the Hormone Therapy drugs for Breast Cancer?

Several drugs are used in hormone therapy for breast cancer, tailored to block or lower hormone levels in the body. Selective estrogen receptor modulators, such as tamoxifen, block estrogen from binding to its receptor on cancer cells. Aromatase inhibitors, including anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin), reduce estrogen production in postmenopausal women. Drugs like fulvestrant (Faslodex) degrade estrogen receptors, preventing cancer cells from using estrogen for growth. Ovarian suppression is another approach, achieved through drugs like goserelin (Zoladex) or surgery to remove the ovaries. These drugs are chosen based on the patient's menopausal status, cancer stage, and other individual factors.

How does Hormone Therapy work for Breast Cancer?

Hormone therapy works by interfering with the hormonal signals that promote the growth of hormone receptor-positive breast cancer cells. Drugs like tamoxifen block estrogen from binding to its receptor, while aromatase inhibitors reduce the production of estrogen in the body. This deprives cancer cells of the hormones they rely on for growth. In some cases, ovarian suppression or removal is used to stop the ovaries from producing estrogen. By targeting specific hormonal pathways, hormone therapy can slow or stop the progression of cancer, prevent recurrence, and improve survival outcomes.

How is Hormone Therapy Administered for Breast Cancer?

Hormone therapy is administered in several forms, depending on the drug and the patient's needs. Oral medications, such as tamoxifen and aromatase inhibitors, are the most common and are taken daily for several years. Injectable drugs like fulvestrant are given through monthly injections, typically in a clinical setting. Ovarian suppression drugs are administered as injections, while surgical removal of the ovaries is a one-time procedure. The duration of hormone therapy varies, with many patients receiving treatment for five to ten years. Regular follow-up appointments are essential to monitor progress and manage any side effects.

Preparation for Hormone Therapy

Preparing for hormone therapy involves a comprehensive evaluation by the healthcare team. Tests are conducted to confirm the hormone receptor status of the tumor, as this determines whether hormone therapy is an appropriate option. Blood tests may be performed to assess overall

health and monitor hormone levels. Patients meet with their oncologist to discuss the treatment plan, expected benefits, potential side effects, and any precautions. Emotional preparation is also important, as long-term treatment can be challenging. Support from loved ones, counseling, and educational resources can help patients feel more prepared and informed.

Effectiveness of Hormone Therapy

Hormone therapy is highly effective for treating hormone receptor-positive breast cancers. It significantly reduces the risk of recurrence in early-stage cancers and helps control the progression of advanced or metastatic disease. Clinical studies have shown that drugs like tamoxifen and aromatase inhibitors improve survival rates and lower the likelihood of cancer returning. The effectiveness of hormone therapy depends on factors such as the type of cancer, the patient's overall health, and adherence to the prescribed treatment regimen. Advances in genetic testing and personalized medicine continue to improve the precision and effectiveness of hormone therapy.

Complications and Side Effects of Hormone Therapy

Hormone therapy can cause a range of side effects, which vary depending on the drug and the patient's individual response. Common side effects of drugs like tamoxifen include hot flashes, vaginal dryness, and mood changes. Aromatase inhibitors may cause joint pain, bone thinning, and an increased risk of fractures. Ovarian suppression can lead to menopausal symptoms such as hot flashes and decreased libido. Rare but serious side effects include blood clots, stroke, and endometrial cancer, particularly with long-term use of tamoxifen. Close monitoring by the healthcare team and proactive management strategies can help minimize these risks.

Post-Hormone Therapy Care and Recovery

After completing hormone therapy, regular follow-up care is essential to monitor for any signs of cancer recurrence. These appointments typically include physical exams, imaging studies, and blood tests. Patients are encouraged to maintain a healthy lifestyle, including a balanced diet, regular exercise, and adequate sleep, to support their overall well-being. Bone density monitoring may be recommended for those who have experienced bone thinning due to aromatase inhibitors. Emotional recovery is also important, and counseling or support groups can help patients navigate the transition to life after treatment.

Life after Hormone Therapy

Life after hormone therapy can bring a mix of emotions, from relief to anxiety about the future. Many patients find comfort in knowing they have taken an important step in reducing their risk of recurrence. Adjusting to life without regular treatment can take time, and some side effects may linger. It is important to stay proactive about health by attending follow-up appointments, maintaining a healthy lifestyle, and addressing any concerns with the healthcare team. Emotional support from loved ones, support groups, or counseling can also play a vital role in helping patients adjust to their new normal.

Conclusion

Hormone therapy is a powerful and effective treatment option for hormone receptor-positive breast cancer, offering hope to millions of patients. By understanding its purpose, process, and potential side effects, patients and their loved ones can feel more informed and empowered to make the best decisions for their care. Advances in medical research continue to improve the effectiveness and safety

of hormone therapy, ensuring that it remains a cornerstone of breast cancer treatment.

References

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015 Oct 3;386(10001):1341-52.
[https://doi.org/10.1016/S0140-6736\(15\)61074-1](https://doi.org/10.1016/S0140-6736(15)61074-1)
2. Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. *N Engl J Med*. 2016 Jul 21;375(3):209-19.
<https://doi.org/10.1056/NEJMoa1604700>
3. Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):122-137.
4. Slamon DJ, Eiermann W, Robert NJ, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. *N Engl J Med*. 2011 Oct 6;365(14):1273-83.
<https://doi.org/10.1056/NEJMoa0910383>
5. Burstein HJ, Temin S, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *J Clin Oncol*. 2014 Jul 20;32(21):2255-69.
<https://doi.org/10.1200/JCO.2013.54.2258>

Notice to the User

This article is part of the '[Public Education Series](#)' initiative by Exon Publications. It was written by professional medical writers for the general public in plain language, based on peer-reviewed articles indexed in PubMed, and further reviewed for scientific accuracy by experts. The views and opinions expressed in this article are believed to be accurate at the time of publication. However, the publisher, editors, and authors cannot be held responsible or liable for

any errors, omissions, or consequences arising from the use of the information provided. The publisher makes no warranties, explicit or implicit, regarding the contents of this article or its use. The information in this article is intended solely for informational purposes and should not be considered medical advice.